Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2018 to Q4 2025

Type / Class
Equity / Common Stock, $0.001 par value
Symbol
AQST on Nasdaq
Shares outstanding
120,192,308
Price per share
$6.46
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
66,072,634
Total reported value
$369,385,993
% of total 13F portfolios
0%
Share change
+18,472,493
Value change
+$106,443,026
Number of holders
150
Price from insider filings
$6.46
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BRATTON DOUGLAS K 11% $23,883,519 10,077,434 BRATTON DOUGLAS K 31 Dec 2024
BlackRock, Inc. 5.3% $35,923,900 6,426,343 BlackRock, Inc. 30 Sep 2025
RTW INVESTMENTS, LP 5.2% $34,937,500 6,250,000 RTW Investments, LP 30 Sep 2025
Venrock Healthcare Capital Partners III, L.P. 2.9% $6,232,593 2,629,786 Venrock Healthcare Capital Partners III, L.P. 31 Dec 2024

As of 30 Sep 2025, 150 institutional investors reported holding 66,072,634 shares of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST). This represents 55% of the company’s total 120,192,308 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) together control 47% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Bratton Capital Management, L.P. 8.2% 9,810,958 0% 100% $54,843,255
BlackRock, Inc. 5.4% 6,525,683 +0.76% 0% $36,478,567
RTW INVESTMENTS, LP 5.2% 6,250,000 0.43% $34,937,500
VANGUARD GROUP INC 4.7% 5,662,132 +31% 0% $31,651,318
PERCEPTIVE ADVISORS LLC 3.1% 3,760,099 +72% 0.61% $21,018,953
EcoR1 Capital, LLC 2.2% 2,625,000 0.7% $14,673,750
SAMSARA BIOCAPITAL, LLC 2.1% 2,500,000 1.8% $13,975,000
GEODE CAPITAL MANAGEMENT, LLC 1.7% 2,087,948 +5.6% 0% $11,673,726
STATE STREET CORP 1.3% 1,602,216 +6.3% 0% $8,956,387
Sio Capital Management, LLC 1.2% 1,498,095 +58% 2.1% $8,374,351
MORGAN STANLEY 1.2% 1,410,109 -0.28% 0% $7,882,511
MILLENNIUM MANAGEMENT LLC 1.1% 1,289,329 -57% 0.01% $7,207,349
Blue Owl Capital Holdings LP 1% 1,250,000 +36% 2.2% $6,987,500
BANK OF AMERICA CORP /DE/ 1% 1,222,135 -4.8% 0% $6,831,734
Janney Montgomery Scott LLC 0.92% 1,099,843 +4.4% 0.01% $6,148,000
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.91% 1,088,644 +133% 0.01% $6,085,520
COMMONWEALTH EQUITY SERVICES, LLC 0.88% 1,058,725 0.01% $5,918,000
FEDERATED HERMES, INC. 0.65% 783,778 0.01% $4,381,319
CITADEL ADVISORS LLC 0.64% 768,450 +405% 0% $4,295,636
WASATCH ADVISORS LP 0.6% 724,278 0.02% $4,048,714
NORTHERN TRUST CORP 0.57% 682,868 +6% 0% $3,817,232
Aberdeen Group plc 0.52% 625,000 0.01% $3,493,750
Nantahala Capital Management, LLC 0.5% 600,000 0.21% $3,354,000
HRT FINANCIAL LP 0.47% 560,209 0.01% $3,131,000
Nuveen, LLC 0.45% 544,617 +170% 0% $3,044,409

Institutional Holders of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 953,919 $6,129,996 +$1,448,963 $6.46 12
2025 Q3 66,072,634 $369,385,993 +$106,443,026 $5.59 150
2025 Q2 47,601,655 $157,593,347 +$12,692,469 $3.31 115
2025 Q1 44,051,858 $127,751,172 -$2,587,454 $2.90 120
2024 Q4 43,216,028 $153,849,274 -$13,656,379 $3.56 112
2024 Q3 46,754,842 $232,438,181 +$19,238,551 $4.98 116
2024 Q2 42,393,620 $110,226,202 -$9,121,899 $2.60 94
2024 Q1 41,491,141 $176,751,489 +$87,793,508 $4.26 96
2023 Q4 29,812 $60,220 +$60,220 $2.02 1
2023 Q3 13,082,950 $20,018,501 +$5,799,574 $1.53 45
2023 Q2 19,057,274 $31,444,857 +$6,895,262 $1.65 53
2023 Q1 14,934,999 $17,025,675 +$180,518 $1.14 34
2022 Q4 14,914,775 $13,452,963 -$886,423 $0.90 34
2022 Q3 15,844,035 $18,532,000 -$593,935 $1.17 38
2022 Q2 16,680,936 $10,612,785 -$1,195,287 $0.64 36
2022 Q1 15,540,428 $40,561,854 -$1,907,068 $2.61 48
2021 Q4 15,964,545 $62,101,046 +$1,738,359 $3.89 49
2021 Q3 14,777,526 $64,432,510 -$2,004,702 $4.36 44
2021 Q2 15,049,593 $59,751,877 -$7,368,229 $3.97 54
2021 Q1 15,416,125 $80,134,974 -$14,506,000 $5.20 61
2020 Q4 18,246,453 $97,616,992 -$4,073,076 $5.35 64
2020 Q3 19,883,853 $96,529,634 +$6,814,712 $4.85 57
2020 Q2 18,511,116 $89,957,616 +$16,357,642 $4.86 55
2020 Q1 15,971,551 $35,033,099 -$11,248,818 $2.19 42
2019 Q4 17,424,629 $100,933,262 +$20,575,217 $5.82 53
2019 Q3 13,273,699 $42,211,449 -$3,516,423 $3.18 30
2019 Q2 14,515,688 $60,962,876 -$1,004,982 $4.20 37
2019 Q1 14,381,636 $99,376,199 +$1,092,881 $6.91 44
2018 Q4 14,369,495 $90,526,000 -$232,037,048 $6.30 35
2018 Q3 16,085,109 $281,644,000 +$281,643,584 $17.51 43